Sarepta

Sarepta Therapeutics, Inc. is a biopharmaceutical company that has been committed to discovering and developing precise gene therapies for rare neuromuscular diseases. Sarepta's unique technology has generated a variety of RNA-based therapeutic approaches, including its leading clinical candidate eteplirsen, which is used to treat Duchenne muscular dystrophy.